These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 24778069

  • 1. Early metabolic response on 18F-fluorodeoxyglucose-positron-emission tomography/computed tomography after concurrent chemoradiotherapy for advanced stage III non-small cell lung cancer is correlated with local tumor control and survival.
    Jeong JU, Chung WK, Nam TK, Song JY, Yoon MS, Kim YC, Kim KS, Oh IJ, Ban HJ, Kwon SY, Bom HS, Ahn SJ.
    Anticancer Res; 2014 May; 34(5):2517-23. PubMed ID: 24778069
    [Abstract] [Full Text] [Related]

  • 2. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.
    Hyun SH, Choi JY, Kim K, Kim J, Shim YM, Um SW, Kim H, Lee KH, Kim BT.
    Ann Surg; 2013 Feb; 257(2):364-70. PubMed ID: 22968069
    [Abstract] [Full Text] [Related]

  • 3. Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.
    Hyun SH, Ahn HK, Ahn MJ, Ahn YC, Kim J, Shim YM, Choi JY.
    AJR Am J Roentgenol; 2015 Sep; 205(3):623-8. PubMed ID: 26295651
    [Abstract] [Full Text] [Related]

  • 4. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H, Wroblewski K, Liao S, Kampalath R, Penney BC, Zhang Y, Pu Y.
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [Abstract] [Full Text] [Related]

  • 5. Value of metabolic tumor volume on repeated 18F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Huang W, Fan M, Liu B, Fu Z, Zhou T, Zhang Z, Gong H, Li B.
    J Nucl Med; 2014 Oct; 55(10):1584-90. PubMed ID: 25214640
    [Abstract] [Full Text] [Related]

  • 6. The predictive value of 18F-FDG PET-CT for assessing the clinical outcomes in locally advanced NSCLC patients after a new induction treatment: low-dose fractionated radiotherapy with concurrent chemotherapy.
    Mattoli MV, Massaccesi M, Castelluccia A, Scolozzi V, Mantini G, Calcagni ML.
    Radiat Oncol; 2017 Jan 05; 12(1):4. PubMed ID: 28057034
    [Abstract] [Full Text] [Related]

  • 7. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
    Lee VH, Chan WW, Lee EY, Choy TS, Ho PP, Leung DK, Lam KO, Kwong DL, Leung TW, Khong PL.
    Am J Clin Oncol; 2016 Aug 05; 39(4):355-62. PubMed ID: 24710123
    [Abstract] [Full Text] [Related]

  • 8. The early predictive value of a decrease of metabolic tumor volume in repeated (18)F-FDG PET/CT for recurrence of locally advanced non-small cell lung cancer with concurrent radiochemotherapy.
    Huang W, Liu B, Fan M, Zhou T, Fu Z, Zhang Z, Li H, Li B.
    Eur J Radiol; 2015 Mar 05; 84(3):482-488. PubMed ID: 25533718
    [Abstract] [Full Text] [Related]

  • 9. Prognostic importance of 18F-fluorodeoxyglucose uptake by positron emission tomography for stage III non-small cell lung cancer treated with definitive chemoradiotherapy.
    Kanyilmaz G, Benli Yavuz B, Aktan M, Sahin O.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020 Mar 05; 39(1):20-26. PubMed ID: 31668790
    [Abstract] [Full Text] [Related]

  • 10. Prognostic value of preoperative metabolic tumor volumes on PET-CT in predicting disease-free survival of patients with stage I non-small cell lung cancer.
    Lin Y, Lin WY, Kao CH, Yen KY, Chen SW, Yeh JJ.
    Anticancer Res; 2012 Nov 05; 32(11):5087-91. PubMed ID: 23155285
    [Abstract] [Full Text] [Related]

  • 11. Effect of PET/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer.
    Ercelep O, Alan O, Sahin D, Telli TA, Salva H, Tuylu TB, Babacan NA, Kaya S, Dane F, Ones T, Alkis H, Adli M, Yumuk F.
    Clin Transl Oncol; 2019 Apr 05; 21(4):499-504. PubMed ID: 30229391
    [Abstract] [Full Text] [Related]

  • 12. Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.
    Ohri N, Piperdi B, Garg MK, Bodner WR, Gucalp R, Perez-Soler R, Keller SM, Guha C.
    Lung Cancer; 2015 Jan 05; 87(1):23-7. PubMed ID: 25468149
    [Abstract] [Full Text] [Related]

  • 13. Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial.
    Machtay M, Duan F, Siegel BA, Snyder BS, Gorelick JJ, Reddin JS, Munden R, Johnson DW, Wilf LH, DeNittis A, Sherwin N, Cho KH, Kim SK, Videtic G, Neumann DR, Komaki R, Macapinlac H, Bradley JD, Alavi A.
    J Clin Oncol; 2013 Oct 20; 31(30):3823-30. PubMed ID: 24043740
    [Abstract] [Full Text] [Related]

  • 14. Prognostic value of (18) F-fluoroazomycin arabinoside PET/CT in patients with advanced non-small-cell lung cancer.
    Saga T, Inubushi M, Koizumi M, Yoshikawa K, Zhang MR, Tanimoto K, Horiike A, Yanagitani N, Ohyanagi F, Nishio M.
    Cancer Sci; 2015 Nov 20; 106(11):1554-60. PubMed ID: 26292100
    [Abstract] [Full Text] [Related]

  • 15. Is ¹⁸F-fluorodeoxyglucose positron emission tomography-based metabolic response superior to Response Evaluation Criteria In Solid Tumors-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of untreated patients with advanced non-small cell lung cancer?
    Yang JJ, Wang SX, Zhong WZ, Xu CR, Yan HH, Wu YL.
    Nucl Med Commun; 2011 Dec 20; 32(12):1113-20. PubMed ID: 21934546
    [Abstract] [Full Text] [Related]

  • 16. Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy.
    Ohno Y, Koyama H, Yoshikawa T, Matsumoto K, Aoyama N, Onishi Y, Sugimura K.
    AJR Am J Roentgenol; 2012 Jan 20; 198(1):75-82. PubMed ID: 22194481
    [Abstract] [Full Text] [Related]

  • 17. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR, Chung SK, Park HL, Choi WH, Kim YK, Lee KY, Wang YP.
    Biomed Mater Eng; 2014 Jan 20; 24(6):3091-103. PubMed ID: 25227018
    [Abstract] [Full Text] [Related]

  • 18. Metabolic activity on [18f]-fluorodeoxyglucose-positron emission tomography/computed tomography and glucose transporter-1 expression might predict clinical outcomes in patients with limited disease small-cell lung cancer who receive concurrent chemoradiation.
    Lee J, Kim JO, Jung CK, Kim YS, Yoo IeR, Choi WH, Jeon EK, Hong SH, Chun SH, Kim SJ, Kim YK, Kang JH.
    Clin Lung Cancer; 2014 Mar 20; 15(2):e13-21. PubMed ID: 24368212
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The prognostic significance of maximum standardized uptake value of primary tumor in surgically treated non-small-cell lung cancer patients: analysis of 413 cases.
    Billè A, Okiror L, Skanjeti A, Errico L, Arena V, Penna D, Ardissone F, Pelosi E.
    Clin Lung Cancer; 2013 Mar 20; 14(2):149-56. PubMed ID: 22682667
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.